Novartis Pharm patent expiration

1. Afinitor Disperz patent expiration

AFINITOR DISPERZ's oppositions filed in EPO
Can you believe AFINITOR DISPERZ received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6004973 NOVARTIS PHARM Pharmaceutical compositions comprising rafamycin coprecipitates
Jul, 2016

(8 years ago)

US6004973

(Pediatric)

NOVARTIS PHARM Pharmaceutical compositions comprising rafamycin coprecipitates
Jan, 2017

(7 years ago)

US5665772 NOVARTIS PHARM O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants
Sep, 2019

(4 years ago)

US7297703 NOVARTIS PHARM Macrolides
Dec, 2019

(4 years ago)

US5665772

(Pediatric)

NOVARTIS PHARM O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants
Mar, 2020

(4 years ago)

US7297703

(Pediatric)

NOVARTIS PHARM Macrolides
Jun, 2020

(4 years ago)

US8778962 NOVARTIS PHARM Treatment of solid tumors with rapamycin derivatives
Feb, 2022

(2 years ago)

US8778962

(Pediatric)

NOVARTIS PHARM Treatment of solid tumors with rapamycin derivatives
Aug, 2022

(1 year, 10 months ago)

US8617598 NOVARTIS PHARM Pharmaceutical compositions comprising colloidal silicon dioxide
Sep, 2022

(1 year, 9 months ago)

US8617598

(Pediatric)

NOVARTIS PHARM Pharmaceutical compositions comprising colloidal silicon dioxide
Mar, 2023

(1 year, 3 months ago)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-630) Oct 29, 2013
New Chemical Entity Exclusivity(NCE) Mar 30, 2014
Pediatric Exclusivity(PED) Apr 29, 2018
Orphan Drug Exclusivity(ODE) Oct 29, 2017
New Indication(I-773) Apr 10, 2021
Orphan Drug Exclusivity(ODE-169) Apr 10, 2025

Drugs and Companies using EVEROLIMUS ingredient

NCE-1 date: 29 April, 2017

Market Authorisation Date: 29 August, 2012

Treatment: Adjunctive treatment of patients with tsc-associated partial-onset seizures

Dosage: TABLET, FOR SUSPENSION

How can I launch a generic of AFINITOR DISPERZ before it's drug patent expiration?
More Information on Dosage

AFINITOR DISPERZ family patents

Family Patents

2. Tabrecta patent expiration

TABRECTA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8461330 NOVARTIS PHARM Imidazotriazines and imidazopyrimidines as kinase inhibitors
Nov, 2027

(3 years from now)

US7767675 NOVARTIS PHARM Imidazotriazines and imidazopyrimidines as kinase inhibitors
Nov, 2027

(3 years from now)

US8420645 NOVARTIS PHARM Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
Jun, 2031

(6 years from now)

US10596178 NOVARTIS PHARM Tablet formulation of 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl) imidazo [1,2-B] [1,2,4] triazin-2-yl] benzamide
Jul, 2035

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8901123 NOVARTIS PHARM Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-B][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
May, 2029

(4 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 06, 2025
Orphan Drug Exclusivity(ODE-291) May 06, 2027

Drugs and Companies using CAPMATINIB HYDROCHLORIDE ingredient

NCE-1 date: 06 May, 2024

Market Authorisation Date: 06 May, 2020

Treatment: Use for the treatment of patients with metastatic non-small cell lung cancer (nsclc) with a mesenchymal-epithelial transition (met) exon 14 skipping mutation

Dosage: TABLET

More Information on Dosage

TABRECTA family patents

Family Patents